Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : HUMA save search
Humacyte to Host Virtual KOL Event “Hemodialysis Access: A Crossroads of Care,” on March 28, 2024
Published: 2024-03-26 (Crawled : 20:00) - globenewswire.com
HUMA | $3.59 15.06% 13.09% 5.6M
|
Manufacturing
|
| O: 2.61%
H: 2.86%
C: -1.59%
Humacyte Fourth Quarter and Year End 2023 Financial Results and Business Update
Published: 2024-03-22 (Crawled : 11:00) - globenewswire.com
HUMA | $3.59 15.06% 13.09% 5.6M
|
Manufacturing
|
| O: 0.83%
H: 0.83%
C: -8.82%
business year update financial results
Humacyte to Present 2023 Fourth Quarter and Year-End Financial Results and Provide Corporate Update on March 22, 2024
Published: 2024-03-18 (Crawled : 12:00) - globenewswire.com
HUMA | $3.59 15.06% 13.09% 5.6M
|
Manufacturing
|
| O: 5.86%
H: 5.25%
C: 2.33%
update financial results
Humacyte, Inc. to Present at the TD Cowen 44th Annual Health Care Conference
Published: 2024-03-01 (Crawled : 14:00) - globenewswire.com
HUMA | $3.59 15.06% 13.09% 5.6M
|
Manufacturing
|
| O: -31.03%
H: 17.0%
C: 8.0%
conference health care
Humacyte, Inc. Announces Pricing of $40.2 Million Public Offering of Common Stock
Published: 2024-03-01 (Crawled : 03:00) - globenewswire.com
HUMA | $3.59 15.06% 13.09% 5.6M
|
Manufacturing
|
| O: -31.03%
H: 17.0%
C: 8.0%
million offering
Humacyte, Inc. Announces Proposed Public Offering of Common Stock
Published: 2024-02-29 (Crawled : 21:00) - globenewswire.com
HUMA | $3.59 15.06% 13.09% 5.6M
|
Manufacturing
|
| O: -31.03%
H: 17.0%
C: 8.0%
offering
Human Acellular Vessel™ (HAV™) Biologics License Application Granted Priority Review by U.S. FDA for the Treatment of Vascular Trauma
Published: 2024-02-09 (Crawled : 13:00) - globenewswire.com
HUMA | $3.59 15.06% 13.09% 5.6M
|
Manufacturing
|
| O: 8.13%
H: 7.96%
C: 7.08%
fda license granted review treatment application
Humacyte Submits Biologics License Application (BLA) to U.S. FDA Seeking Approval of Human Acellular Vessel™ (HAV™) for the Treatment of Vascular Trauma
Published: 2023-12-12 (Crawled : 13:00) - globenewswire.com
HUMA | $3.59 15.06% 13.09% 5.6M
|
Manufacturing
|
| O: 0.36%
H: 2.18%
C: -0.36%
fda license approval treatment application
Humacyte to Present at the Piper Sandler 35th Annual Healthcare Conference
Published: 2023-11-24 (Crawled : 13:00) - globenewswire.com
HUMA | $3.59 15.06% 13.09% 5.6M
|
Manufacturing
|
| O: 0.39%
H: 5.66%
C: 1.17%
conference
Humacyte Announces Two Presentations at the VEITHsymposium® of Positive Clinical Results of the Human Acellular Vessel™ (HAV™) in the Treatment of Vascular Trauma
Published: 2023-11-17 (Crawled : 13:00) - globenewswire.com
HUMA | $3.59 15.06% 13.09% 5.6M
|
Manufacturing
|
| O: 1.64%
H: 4.03%
C: 1.61%
veithsymposium positive treatment results
Humacyte Third Quarter 2023 Financial Results and Business Update
Published: 2023-11-09 (Crawled : 21:00) - globenewswire.com
HUMA | $3.59 15.06% 13.09% 5.6M
|
Manufacturing
|
| O: 2.26%
H: 4.87%
C: 3.98%
business update financial results
Humacyte to Present Third Quarter Financial Results and Provide Corporate Update on November 9, 2023
Published: 2023-11-02 (Crawled : 20:00) - globenewswire.com
HUMA | $3.59 15.06% 13.09% 5.6M
|
Manufacturing
|
| O: 1.9%
H: 11.63%
C: 3.26%
update financial results
Humacyte Publishes Preclinical Results Showing Human Acellular Vessel™ (HAV™) Patency as Modified Blalock–Taussig–Thomas Shunt in Juvenile Primate Model-Outcomes exhibit potential of HAV for palliative treatment of congenital heart disease-
Published: 2023-10-16 (Crawled : 22:00) - biospace.com/
HUMA | $3.59 15.06% 13.09% 5.6M
|
Manufacturing
|
| O: 0.39%
H: 2.32%
C: 0.39%
treatment preclinical heart potential results
Humacyte Publishes Preclinical Results Showing Human Acellular Vessel™ (HAV™) Patency as Modified Blalock–Taussig–Thomas Shunt in Juvenile Primate Model
Published: 2023-10-16 (Crawled : 13:00) - globenewswire.com
HUMA | $3.59 15.06% 13.09% 5.6M
|
Manufacturing
|
| O: 0.39%
H: 2.32%
C: 0.39%
preclinical results
Humacyte to Present at the Cantor Global Healthcare Conference
Published: 2023-09-21 (Crawled : 20:00) - globenewswire.com
HUMA | $3.59 15.06% 13.09% 5.6M
|
Manufacturing
|
| O: 0.34%
H: 1.19%
C: -2.04%
conference global
Humacyte to Host In-Person KOL Event at the New York EDITION on September 20, 2023
Published: 2023-09-18 (Crawled : 20:00) - globenewswire.com
HUMA | $3.59 15.06% 13.09% 5.6M
|
Manufacturing
|
| O: 0.0%
H: 0.66%
C: -0.66%
Humacyte Announces Positive Top Line Results from Phase 2/3 Trial of Human Acellular Vessel™ (HAV™) in Treatment of Patients with Vascular Trauma
Published: 2023-09-12 (Crawled : 11:00) - globenewswire.com
HUMA | $3.59 15.06% 13.09% 5.6M
|
Manufacturing
|
| O: 5.41%
H: 6.41%
C: -0.51%
positive treatment trial results
Humacyte to Announce Top Line Data from Phase 2/3 V005 Trial in Vascular Trauma Evaluating its Human Acellular Vessel™ (HAV™) Tuesday, September 12, 2023 at 8:00 AM ET
Published: 2023-09-11 (Crawled : 21:00) - globenewswire.com
HUMA | $3.59 15.06% 13.09% 5.6M
|
Manufacturing
|
| O: 5.41%
H: 6.41%
C: -0.51%
trial
Results From Mayo Clinic Clinical Study of Humacyte’s Human Acellular Vessel™ (HAV™) in Treatment of Patients with Chronic Limb Ischemia Presented at Midwestern Vascular Conference
Published: 2023-09-11 (Crawled : 12:00) - globenewswire.com
HUMA | $3.59 15.06% 13.09% 5.6M
|
Manufacturing
|
| O: 1.06%
H: 6.79%
C: -3.39%
conference treatment results study
Humacyte Presents Clinical Performance of Human Acellular Vessel™ (HAV™) From Ukrainian Humanitarian Program
Published: 2023-08-15 (Crawled : 12:00) - globenewswire.com
HUMA | $3.59 15.06% 13.09% 5.6M
|
Manufacturing
|
| O: -3.47%
H: 18.69%
C: 14.87%
program
Gainers vs Losers
| 53% | 47% |
Top 10 Gainers
HUBC | $1.52 17.83% 4.7M
|
n/a
NVCT | $6.88 2.38% 2.8K
|
BKNG | $3456.65 0.77% 13K
|
Consumer Services
ED | News | $91.43 0.58% 75K
|
Utilities
CWST | $92.75 0.41% 13K
|
Industrial Services
MBI | $6.075 0.41% 12K
|
Finance
BCS | $9.27 0.33% 140K
|
Finance
RVMD S | $35.86 0.08% 36K
|
Health Technology
BIIB | $190.59 0.04% 50K
|
Health Technology
CMG | $2898.49 -0.33% 290
|
Consumer Services
Your saved searches
Save your searches and get alerts when important news are released.